AnaptysBio, Inc. (ANAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Viewpoint - AnaptysBio is undergoing a significant transformation, planning to separate into two distinct businesses by the second quarter of 2025, referred to as Biopharma Co and Royalty Management Co [1] Group 1: Business Structure - The separation will create two entities: Biopharma Co, which will focus on clinical assets, and Royalty Management Co [1] - Biopharma Co will be anchored by three clinical assets, with ANB033 being a key driver for the operating business [2] Group 2: Clinical Development - ANB033 is currently enrolling patients in a Phase Ib trial for celiac disease and initiating a second Phase Ib trial for eosinophilic esophagitis (EoE) [2] - Rosnilimab, another asset, has shown positive Phase IIb results in an arthritis trial, with plans to explore Phase III development and secure necessary capital [2] - An end of Phase II meeting with the FDA is scheduled for the next quarter to discuss the progression of Rosnilimab [2]